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Abstract: Information concerning the mechanisms underlying oxidative stress and low-grade in-
flammation in young healthy women predisposing eventually to future diseases is scarce. We
investigated the relationship of oxidative stress and high-sensitivity C-reactive protein (hsCRP) in
fertile-age women by oral combined contraceptive (OC) use. Caucasian Italian healthy non-obese
women (n = 290; 100 OC-users; 190 non-OC-users; mean age 23.2 ± 4.7 years) were analyzed. Blood
hydroperoxides, as oxidative stress biomarkers, were assessed by Free Oxygen Radical Test (FORT).
Serum hsCRP was determined by an ultra-sensitive method (hsCRP). Markedly elevated oxida-
tive stress (≥400 FORT Units) was found in 77.0% of OC-users and 1.6% of non-OC-users, odds
ratio (OR) = 209, 95% CI = 60.9–715.4, p < 0.001. Elevated hsCRP levels ≥ 2.0 mg/L, considered
risky for cardiovascular diseases (CVDs), were found in 41.0% of OC-users and 9.5% of non-OC-
users, OR = 6.6, 95%CI 3.5–12.4, p < 0.001. Hydroperoxides were strongly positively correlated to
hsCRP in all women (rs = 0.622, p < 0.001), in OC-users (rs = 0.442, p < 0.001), and in non-OC-users
(rs = 0.426, p < 0.001). Women with hydroperoxides ≥ 400 FORT Units were eight times as likely to
have hsCRP ≥ 2 mg/L. In non-OC-users only, hydroperoxides values were positively correlated
with weight and body mass index, but negatively correlated with red meat, fish and chocolate
consumption. Our research is the first finding a strong positive correlation of serum hydroperoxides
with hsCRP, a marker of low-grade chronic inflammation, in young healthy women. Further research
is needed to elucidate the potential role of these two biomarkers in OC-use associated side-effects,
like thromboembolism and other CVDs.
Keywords: lipid peroxidation; free radicals; inflammation; contraceptive pill; thromboembolism;
hormonal contraception; estrogen; progestin; third generation pill; alimentary habits
1. Introduction
The biological pathways and the biomarkers associated with the side effects of hor-
monal contraception remain elusive and require additional research. Large studies and
meta-analysis have assessed the association of oral combined contraceptive (OC) use
with major complications, mainly cardiovascular diseases (CVDs) like arterial and venous
thromboembolism (VTE), myocardial infarction, ischemic stroke, pulmonary embolism,
peripheral arterial disease, and sudden cardiac death [1–11] and also some types of cancer
including breast, uterine cervix, as well as liver and bile duct cancers [12–14]. Moreover, a
higher risk for preterm birth in women who had used OCs before pregnancy compared
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with a control group was demonstrated [15]. Some evidence shows also a correlation of
OC use with mood disorders and depression [16,17].
Presently, limited research assessed oxidative stress [18–23] and low-grade inflamma-
tory status [24–31] in pre-menopausal women OC-users, two conditions that have been
independently implicated in several pathologies, including CVDs and cancer. Rather
surprisingly no study examined the relationship between oxidative stress and low-grade
inflammatory status in a sample of childbearing age women according to OC use. Impor-
tantly, both oxidative stress and low-grade inflammatory status can, at least in part, be
modulated by lifestyles [25,29,32–37].
The overproduction of reactive oxygen species (ROS), like superoxide anion (O2•−),
hydroxyl radical (HO•), peroxide (O22−), when not balanced by the antioxidant defence
(including enzymatic and non-enzymatic molecules) causes oxidative stress [38]. Free
radicals can attack various molecules (namely lipids, nucleic acids, proteins, etc.) becoming
deleterious for the human body because of the formation of altered molecules [38]. It
is well established that oxidative stress has major roles in the pathogenesis of several
diseases such as inflammatory, cardiovascular, muscular, and neurodegenerative diseases
and cancer [38]. However, ROS have also physiological positive roles as free radicals
contribute in signalling devoted to regulate cell functions and inflammatory responses to
microorganisms and xenobiotics [38].
Various biomarkers have been used to evaluate oxidative stress in fertile age women
of the general population [19–23,33,35] suggesting an increase associated to hormonal
contraception. In young female athletes a recent research showed increased oxidative stress
in OC-users compared to non-OC-users [18].
On the other hand, there is some evidence that OC use raises the chronic low-grade
inflammatory status as assessed by the increase of high-sensitivity C-reactive protein
(hsCRP) [24–28,31]. Elevation of hsCRP in young women [16] implies several potential
adverse effects including CVD risk [39,40], endothelial damage, myocardial infarction, and
thromboembolic events [2]. In women, for assessment of CVD risk stratification, the hsCRP
cutoff concentrations of 2 mg/L and 3 mg/L were frequently used as risky, and <0.5 mg/L
as no risky/protective [41].
The relation of C-reactive protein to oxidative stress was previously investigated
in some pathologic conditions like hypertension [42], renal failure [43] or dilated car-
diomyopathy [44]. However, this relationship was never investigated in healthy women.
Progress in the understanding of the regulatory mechanisms underlying oxidative stress
and chronic low-grade inflammation can furnish insights for the prevention of OC side
effects in women. Moreover, it is interesting to establish whether the two serum biomarkers
levels are potentially modifiable by lifestyle and alimentary habits of young women.
The general aim of the study was to investigate whether serum hydroperoxides (as
indicator of oxidative stress) and hsCRP (as marker of chronic low-grade inflammation)
levels were interrelated in young women also according to OC use.
2. Materials and Methods
2.1. Design and Setting of the Study
The study was conducted on healthy Italian adult women enrolled in the years up
to September 2019; none of the volunteers were athletes, to avoid confounding effects of
physical exercise [25].
All participants attended once the Medical Department laboratory (University of
Udine, Italy) early in the morning (8–10 am) after 12 h fasting. A finger capillary and
a venous blood withdrawal [24,25] was thus taken on seated subjects [18,45]. The day
before, volunteers were asked to refrain from alcohol and supplement consumption as
well as from physical activity. Menstrual cycle phase was not accounted for; however,
menstruation bleeding days were avoided (days 1–7 of menstrual cycle) because during
those days oral contraception consists of drug discontinuation or placebo use. Clinical,
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demographic, and habit data were blinded to personnel executing the blood collection and
samples measurements.
2.2. Population
Women (age range 18–46 years) were recruited consecutively; announcements at Udine
University were used to enroll the volunteers. All study participants filled questionnaires
and volunteered for a venous and a finger capillary blood withdrawal. The inclusion
criteria were: (a) no acute (current/recent) infection or chronic disease such as diabetes
mellitus, autoimmune diseases, thyroid or cardiovascular disease, or any tumor [24,25];
(b) absence of pain from whatever cause [46]; (c) no assumption of anti-inflammatory drugs
or antibiotics in the last 2 weeks [24,25], (d) no hormonal drugs other than monophasic
combined contraceptive pills [24,25], (e) not lactating, pregnant, or postmenopausal [47];
(f) no present or past menstrual dysfunction [48]; and (h) no major sleeping disorders [18].
Eligible women for inclusion in the OC-users group were those using a monophasic
combined oral contraceptive for at least 3 months, whereas for inclusion in the non-OC-
users control group, women had never used hormonal contraception or had discontinued
since at least 3 months any hormonal treatment [18,25]. Three-hundred women were
examined for eligibility; at the time of blood withdrawal, 10 women were excluded due to
acute disease potentially affecting the inflammatory status. A total of 290 participants were
thus included in the study (n = 100 OC-users and n = 190 non-OC-users).
Demographic factors, medical history and lifestyle habits (including smoking) were
collected by a questionnaire. Moreover, a 2 weeks long diary allowed to collect alimentary
habits in the form of daily number of servings as already described [18]. Alimentary
supplements consisted of a wide variety of commercial products containing variable
amounts of single or mixed compounds, assumed by women occasionally, intermittently,
or continually. Thus, alimentary supplements were not categorized into specific subgroups,
and a categorical variable (yes or no) designed “supplement use” was employed for
statistical analysis. Body mass index (BMI) was calculated as body mass (kg) divided by
the square of stature (m).
2.3. Ethical Considerations
Written informed consent was obtained from each participant before enrolment and
no compensation or incentive was paid to the participants for this study. The study was
approved by the Institutional Ethical Committee of the Department of Medicine (University
of Udine, number of ethical approval 554), and was conducted according to the rules of the
Declaration of Helsinki (1975).
2.4. Oxidative Stress Assessment
Blood hydroperoxides, mainly consisting of lipid hydroperoxides [18,45], were de-
termined in 20 µL of capillary blood using the Free Oxygen Radical Test (FORT assay;
Callegari, Parma, Italy), a 6 min long colorimetric assay based on the ability of transition
metals to catalyze the breakdown of hydroperoxides (ROOH) into radicals, according to
the Fenton reaction [45]. Results were expressed as FORT Units, whereby 1 FORT Unit
corresponded to 0.26 mg/L H2O2 [45]. Variations of the intra- and inter-assay were both
<5.0%. The range limits of measurable values were ≤160 and ≥600 FORT Units. Four
non-OC-users had FORT values ≤ 160 and were set at 160 FORT Units, whereby 9 OC-users
had ≥600 FORT Units and were set at 600 FORT Units for statistical calculations.
The threshold of 310 FORT Units was used as high cut-off level of hydroperoxides [18],
and a value of 400 FORT Units was employed as very high threshold level of oxida-
tive stress [49].
2.5. C-Reactive Protein Measurement
Just after collection, venous blood was processed for serum separation as already
described [25].
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Serum hsCRP was measured on Olympus AU5400 biochemistry analyzer (Olympus
Diagnostic Systems Group, Brea, CA, USA) using an ultra-sensitive immunoturbidimetric
assay (Olympus System CRP latex). Detection limit of the assay was ≤0.1 mg/L. Samples
with values below the detection limit were set at 0.1 mg/L for statistical calculations. The
intra- and inter-assay variations were 1.1%, and 4.0%, respectively. Stratification of hsCRP
levels were performed at 0.5 mg/L as no risky level, and 2.0 mg/L and 3 mg/L as risky
levels for future CVD, as described [24,39,41].
2.6. Statistical Analysis
Normality of distribution of variables was assessed by the Kolmogorov-Smirnov test.
Gaussian distributed data were shown as mean ± standard deviation (SD). The FORT
and hsCRP data were not normally distributed, thus, their values were shown as median
and interquartile range (IQR, 25th to 75th percentile) and non-parametric tests were used.
Continuous variables were compared by the Mann-Whitney U-test. The comparison of
proportions between groups was assessed by Pearson’s X2-test that was appropriate for
all the categorical variables except for “nulliparity” for which Fisher’s exact test was used.
Crude odds ratios (ORs) and 95% confidence intervals (CIs) were evaluated for categorical
variables. Logistic regression was performed to evaluate the difference in oxidative stress
between groups after adjustment for: age, BMI, smoking, supplement use, chocolate,
fresh vegetable, fruits, red meat and fish servings per week. Bivariate relationships were
evaluated by Spearman Rho test (rs). All tests were 2-sided. Statistical significance was set
at p values < 0.05. At an alpha level of 0.01, we had over 95% power to detect a difference in
the proportion cases with hsCRP ≥ 2 mg/L between the OC-users and the non-OC-users
groups and to find a correlation between hsCRP and FORT Units with rs > 0.4. Statistical
analysis was performed using the Statistical Package for Social Sciences (SPSS for Windows,
SPSS Inc., Chicago, IL, USA).
3. Results
On average, the 290 study women were 23.2 ± 4.71 year-olds, had BMI 21.2 ± 2.31 kg/m2,
97.9% were nulliparous, mostly enrolled at or employed by Udine University, 82.8% had
university level education, 16.6% were smokers, and all had a middle-class socioeconomic
status. Main demographic and lifestyle characteristics and continuous values of oxidative
stress and hsCRP of the 100 OC-users and the 190 non-OC-users are summarized in Table 1.
A normal weight range (BMI 18.0–25.0 kg/m2) was found in 91.4% of women,
9 women were underweight (3.1%, BMI < 18.0 kg/m2), and 16 were overweight (5.5%,
BMI > 25.0 kg/m2); none of the women, however, had a BMI ≥ 30.0 kg/m2. OC-users
had slightly more frequently a university education (89.0%) than non-OC-users (79.5%),
p = 0.041 (Table 1). However, most of the studied parameters were not significantly differ-
ent between OC-users and non-OC-users including smoking habits, coffee and nutritional
supplement use. In our sample, women smoke on average less than 1 cigarette per day.
Only one woman smoked 26 cigarettes per day, none of the other smokers smoked more
than 15 cigarettes per day.
Table 1 shows median (25th to 75th percentile) values of hydroperoxides that were 1.7-
fold higher in OC-users compared to non-users (median 472 vs. 270 FORT Units, p < 0.001).
Values of hsCRP were 3.7-fold higher in OC-users compared to non-users (median 1.31 vs.
0.35 mg/L, p < 0.001).
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(n = 190) p Value
Age a (years) 22.7 ± 3.50 23.4 ± 5.23 0.887 b
Weight a (kg) 60.1 ± 7.59 60.3 ± 8.43 0.921 b
Height a (m) 1.68 ± 5.94 1.69 ± 0.07 0.752 b
Body-mass index a (kg/m2) 21.2 ± 2.24 21.2 ± 2.35 0.993 b
University education, n (%) 89 (89.0) 151 (79.5) 0.041 c
Married, n (%) 5 (5.0) 19 (10.0) 0.142 c
Nulliparity, n (%) 99 (99.0) 185 (97.4) 0.668 d
Smokers, n (%) 21 (21.0) 27 (14.2) 0.139 c
Cigarettes/day a 0.83 ± 2.16 0.75 ± 2.68 0.166 b
Coffee drinkers, n (%) 78 (78.0) 154 (81.1) 0.537 c
Coffee cups e/day 1.2 ± 1.02 1.5 ± 1.19 0.055 b
Nutritional supplement use, n (%) 23 (23.0) 29 (15.3) 0.103 c
Oxidative stress (FORT Units) 472 (403–532) 270 (229–308) <0.001 b
hsCRP (mg/L) 1.31 (0.79–3.34) 0.35 (0.17–0.72) <0.001 b
a Values are mean ± SD or median (25th–75th percentile) as appropriate; b comparison of OC-users and non-OC-users by two-tailed
Mann Whitney test; c comparison of OC-users and non-OC-users by two-tailed chi-square Pearson’s test; d comparison of OC-users
and non-OC-users by two-tailed Fisher’s exact test as appropriate; e Italian espresso coffee cups. Statistically significant differences are
highlighted by bold characters.
3.1. Combined Oral Contraception
A hundred women were using OC from 3 to 144 months. Continuous values of
FORT Units and hsCRP concentration were not correlated with months of OC use (p > 0.05
for both).
OCs had different formulations but all were monophasic combined pills. Pills had
variable progestin components: gestodene (43.0%), drospirenone (24.0%), desogestrel
(12.0%), levonorgestrel (10.0%), cyproterone (4.0%), dienogest (3.0%), clormadinone (2.0%),
and nomegestrolo acetate (2.0%). Overall, among the 100 OC-users second generation pill
preparations (containing levonorgestrel) were used by 10.0%, third generation pill prepa-
rations (having gestodene or desogestrel as progestin) by 55.0%; and fourth generations
pills (containing drospirenone, cyproterone, dienogest, clormadinone and nomegestrolo
acetate) by 35.0% of women. Preparations containing progestogens with the highest risk
of VTE according to recent evidence [5] i.e., those including desogestrel, cyproterone, and
drospirenone were used by 40.0% of OC-users.
Table 2 shows continuous values of hydroperoxides (FORT Units) and hsCRP (mg/L)
in each generation pill users. Use of second generation pill was associated with lower values
of hydroperoxides than third (p = 0.009) and fourth (p = 0.008) generation; conversely, third
and fourth generation did not differ. Concentrations of hsCRP did not vary significantly
among groups.





















(FORT Units) 366 (332–434) 468 (416–530) 491 (434–566) 0.009 0.008 0.236
hsCRP (mg/L) 1.06 (0.83–3.05) 1.21 (0.70–3.39) 1.67 (0.86–3.34) 0.592 0.445 0.898
Second generation pill containing levonorgestrel; third generation pill containing gestodene and desogestrel; and fourth generation
pills containing drospirenone, cyproterone, dienogest, clormadinone and nomegestrolo acetate. a Values are median (25th–75th per-
centile); b comparison between generation pills by two-tailed Mann Whitney test. Statistically significant differences are highlighted by
bold characters.
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Moreover, by analysis of each generation pill vs. others, second generation pill users
compared to all other pills showed lower hydroperoxides (median 366 (IQR 332–434)
vs. 484 (IQR 421–542) FORT Units, p = 0.006), whereas did not differ for hsCRP values
(p = 0.509). Comparison of 55 users of third generation pills with other pill preparations
did not show significant differences for hydroperoxides (p = 0.997) and hsCRP (p = 0.923).
Fourth generation pill users were not different from the other pills in hydroperoxides
(p = 0.083) and hsCRP (p = 0.753). However, by comparing the 40 users of OC at high risk
of thromboembolism (i.e., those containing desogestrel, cyproterone, and drospirenone)
with all the other remaining pills, oxidative stress was higher (median 492 (IQR 442–576)
vs. 444 (IQR 367–502) FORT Units, p = 0.003), although hsCRP did not differ (p = 0.198).
3.2. Stratified Values of Oxidative Stress and hsCRP
Table 3 shows the comparison of OC-users and non-OC-users according to categorized
values of hydroperoxides and of hsCRP.









(95% CI) p Value
a Adjusted OR b
(95%CI) p Value
b
FORT ≥ 310 Units 92 (92.0) 45 (23.7) 37.1 (16.7–82.1) <0.001 100 (30.1–334) <0.001
FORT ≥ 400 Units 77 (77.0) 3 (1.6) 209 (60.9–715) <0.001 342 (69.4–1688) <0.001
hsCRP < 0.5 mg/L 16 (16.0) 118 (62.1) 0.12 (0.06–0.21) <0.001 0.07 (0.03–0.16) <0.001
hsCRP ≥ 2.0 mg/L 41 (41.0) 18 (9.5) 6.64 (3.54–12.4) <0.001 11.1 (4.90–25.2) <0.001
hsCRP ≥ 3.0 mg/L 33 (33.0) 13 (6.8) 6.71 (3.33–13.5) <0.001 8.05 (3.47–18.7) <0.001
FORT, oxidative stress expressed in FORT Units; hsCRP, high-sensitivity C-reactive protein; OR, odds ratio; CI, confidence interval. p value
calculated by two-tailed chi-square Pearson’s or Fisher’s exact test as appropriate. a Univariable OR; b Adjusted for age, body-mass index,
smoking, supplement use, and chocolate, fresh vegetable, fruits, red meat and fish servings per week; Statistically significant differences are
highlighted by bold characters.
A marked difference was noted for hydroperoxides values ≥ 310 FORT Units, which
were detected in 92.0% of OC-users compared to 23.7% of non-OC-users, crude OR = 37.1,
p < 0.001, adjusted OR = 100, p < 0.001. Very high levels of hydroperoxides ≥ 400 FORT
Units were observed in 77.0% of OC-users compared to 1.6% of non-OC-users, crude
OR = 209, p < 0.001, adjusted OR = 342, p < 0.001.
Regarding stratified hsCRP levels, the percentage of subjects with risky hsCRP con-
centrations was significantly higher in OC-users compared to non-OC-users; for the cutoff
value of ≥2 mg/L crude OR 6.64, adjusted OR 11.1, and for the cutoff value of ≥3 mg/L
crude OR 6.71, adjusted OR 8.05. Conversely, non-OC-users were much more likely to
show protective hsCRP < 0.5 mg/L values compared to OC-users (OR 8.60; p < 0.001).
Very few women (n = 6) had hsCRP ≥ 10 mg/L, 5 among the OC-users, and 1 among the
non-OC-users. No woman had hsCRP ≥ 20 mg/L.
Women having elevated hsCRP values were much more likely to show elevated oxida-
tive stress (Table 4). Specifically, among a total of 59 women having risky hsCRP ≥ 2 mg/L,
49 (83%) had FORT ≥ 310 Units and 38 (64%) had FORT ≥ 400 Units; furthermore, among
a total of 46 women having hsCRP ≥ 3 mg/L, 39 (85%) had FORT ≥ 310 Units and 32
(70%) had FORT ≥ 400 Units. On the contrary, women with low protective levels of hsCRP
(<0.5 mg/L) were much less likely to have elevated oxidative stress. Indeed, among the
134 women having protective hsCRP < 0.5 mg/L, only 26 (19%) had FORT ≥ 310 Units and
7 (5.0%) had FORT ≥ 400 Units.
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hsCRP < 0.5 mg/L 26 (19.0) 108 (70.6) 0.10(0.06–0.17)<0.001 7 (8.8) 127 (60.5)
0.06
(0.03–0.14)<0.001
hsCRP ≥ 2.0 mg/L 49 (35.8) 10 (6.5) 7.96(3.84–16.5)<0.001 38 (47.5) 21 (10.0)
8.14
(4.34–15.3)<0.001
hsCRP ≥ 3.0 mg/L 39 (28.5) 7 (4.6) 8.30(3.57–19.3)<0.001 32 (40.0) 14 (6.7)
9.33
(4.62–18.8)<0.001
Two thresholds of elevated hydroperoxides levels (≥310 or ≥400 FORT Units) were compared with the corresponding low hydroperoxides
levels (<310 or <400 FORT Units, respectively) in the whole group of 290 women. OR, odds ratio; CI, confidence interval; p value by
two-tailed chi-squared test. Statistically significant differences are highlighted by bold characters.
By considering the two elevated thresholds of oxidative stress, namely FORT ≥ 310 or
≥400 Units (Table 4), women were roughly 8-fold more likely to have elevated hsCRP levels.
In a refined analysis, stratified levels of FORT ≥ 400 Units and hsCRP concentrations
were examined separately in 100 OC-users. Among 77 OC-users with FORT ≥ 400 Units
37 (48%) had hsCRP ≥ 2 mg/L and 31 (40%) had hsCRP ≥ 3 mg/L, whereas among
23 OC-users with FORT < 400 Units only 4 (17.4%) had hsCRP ≥ 2 mg/L and 2 (8.7%)
had hsCRP ≥ 3 mg/L, with OR = 4.39, 95%CI 1.37–14.1, p = 0.009, and OR = 7.08, 95%CI
1.55–32.4, p = 0.005, respectively. OC-users with FORT ≥ 400 Units were less likely to have
CRP < 0.5 mg/L, OR = 0.16, 95%CI 0.05–0.49, p = 0.002.
Table 5 summarizes the correlations of hydroperoxides continuous values (in FORT
Units) with other biomarkers in all 290 study women, and separately in the 100 OC-
users and 190 non-OC-users. FORT Units were highly positively correlated with hsCRP
concentrations with p < 0.001 in each of the 3 groups (rs = 0.622, 0.442, 0.426, respectively).
A positive association of FORT Units with body weight was found in non-OC-users only
(p = 0.005). Oxidative stress showed significant positive associations with BMI in all women
(p = 0.047) and non-OC-users (p = 0.001). Concerning the alimentary habits, hydroperoxides
showed significant inverse associations with red meat, fish and chocolate servings in all
women (p = 0.004, 0.027, 0.041, respectively) and non-OC-users (p = 0.007, 0.045, 0.028,
respectively). Finally, we found an inverse correlation of hydroperoxides in all women
with fruits (p = 0.035) and total meat servings (p = 0.029). Remarkably, in OC-users none of
the examined demographic, lifestyle/alimentary habits were associated with FORT Units,
with exception of hsCRP.












hsCRP (mg/L) 0.622, <0.001 0.442, <0.001 0.426, <0.001
Age, years 0.041, 0.489 0.047, 0.644 0.080, 0.274
Weight, kg 0.092, 0.122 −0.011, 0.910 0.207, 0.005
Height, cm −0.013, 0.822 −0.103, 0.307 0.027, 0.715
BMI, kg/m2 0.118, 0.047 0.061, 0.547 0.252, 0.001
Cigarettes/day 0.084, 0.152 −0.002, 0.985 0.029, 0.696
Coffee cups a/day −0.099, 0.098 −0.118, 0.251 0.029, 0.701
Tea cups/day 0.079, 0.188 0.078, 0.447 −0.046, 0.540
Milk cups/week 0.042, 0.517 b 0.135, 0.204 d 0.032, 0.700 f












Yogurt, 125 g servings/week −0.035, 0.593 b −0.097, 0.364 d −0.053, 0.521 f
Cheese, 50 g servings/week −0.034, 0.602 b −0.006, 0.955 d 0.040, 0.630 f
Rice, 80 g servings/week −0.031, 0.634 b 0.130, 0.222 d −0.138, 0.094 f
Pasta, 100 g servings/week 0.047, 0.473 b −0.122, 0.252 d 0.103, 0.210 f
Fruits, 200 g servings/week −0.136, 0.035 b −0.167, 0.115 d −0.129, 0.116 f
Tomatoe/eggplant/pepper, plates/week 0.009, 0.891 b −0.133, 0.224 d −0.008, 0.930 f
Fresh vegetables, plates/week −0.087, 0.180 b −0.066, 0.537 d −0.062, 0.453 f
Legumes, plates/week −0.023, 0.726 −0.111, 0.298 d 0.029, 0.727 f
Eggs, number/week −0.002, 0.972 b −0.051, 0.641 d 0.051, 0.542 f
Red meat, 150 g servings/week −0.190, 0.004 b −0.031, 0.777 d −0.222, 0.007 f
Total meat (any type), 150 g servings/week −0.141, 0.029 b 0.022, 0.839 d −0.090, 0.273 f
Sausages, 50 g servings/week 0.000, 0.995 b 0.043, 0.686 d 0.054, 0.511 f
Fish, 200 g servings/week −0.143, 0.027 b −0.039, 0.717 d −0.164, 0.045 f
Sweet cakes, 50 g servings/week −0.055, 0.393 b −0.025, 0.813 d 0.072, 0.382 f
Chocolate, 50 g servings/week −0.132, 0.041 b −0.050, 0.640 d −0.180, 0.028 f
Wine, 125 mL glasses/week 0.033, 0.596 c 0.046, 0.665 e −0.005, 0.945 g
Beer, 200 mL glasses/week 0.080, 0.199 c 0.096, 0.360 e 0.057, 0.466 g
Spirits, 40 mL glasses/week −0.008, 0.900 c −0.069, 0.510 e 0.103, 0.190 g
Two-sided Spearman correlations (rs) between continuous values of FORT Units and other biomarker continuous values are summarized
for all women sample (n = 290), and separately for the 100 OC-users and the 190 non-OC-users. a Italian espresso coffee cups; b data
available for 240 women; c data available for 258 women; d data available for 90 OC-user women; e data available for 93 OC-user women;
f data available for 150 OC-user women; g data available for 165 non-OC-user women. Statistically significant differences are highlighted
by bold characters.
4. Discussion
The main outcomes of the present study are: (1) Elevated oxidative stress levels were
found in non-athlete OC-users belonging to the general population of healthy young
women; (2) OC-use resulted in chronic inflammation, confirming previous studies per-
formed in lower number of women or different ethnic groups; (3) Oxidative stress and
hsCRP were strongly correlated; (4) Body mass (as well as BMI) and some alimentary
habits modulated oxidative stress in non-OC-users only.
4.1. Oxidative Stress
Oxidative stress was evaluated by an assay measuring hydroperoxides (expression
mainly of lipid peroxidation) [33,45,50], that constitutes only one of the possible indirect
markers to assess oxidative stress status [51]; however, the FORT assay has been validated to
assess oxidative stress in human blood by various recent studies [18,32,45,52]. Specifically,
the FORT assay has been validated for clinical use in women and has the advantage to
be easily used in outpatient facilities [32,52]. Lewis, et al. [52] determined a value for
individual biological variations of the FORT assay equal to 5.0%.
We found a remarkable elevated frequency of high oxidative stress levels in healthy
OC-users; by the cutoff value of ≥310 FORT Units 92.0% (crude OR = 37, adjusted OR
= 100 compared to non-OC-users), and by the cutoff value of ≥400 FORT Units 77.0%
(crude OR = 209, adjusted OR = 342). The median of continuous FORT Units was almost
2-fold higher in OC-users than in non-OC-users. In our study, among OC-users oxidative
stress was not associated to their lifestyles and alimentary habits according to the study
parameters. It appears that pro-oxidant effects of OCs likely overwhelmed antioxidant
effects of lifestyle/alimentary good habits in OC-users. At variance, oxidative stress in non-
OC-users was negatively associated with some alimentary habits, specifically chocolate, red
meat and fish servings per week. Our findings are consistent with the known antioxidant
properties of some foods [53–55]. It is to mention that in our study fruits consumption had
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a negative correlation with oxidative stress in all the 290 women, however, in the distinct
subgroups of 100 OC-users and 190 non-OC-users such negative correlation did not reach
statistical significance, thus, fruits effects will require further research [54].
We did not found oxidative stress association with smoking and supplement con-
sumption in the study women. The number of cigarettes smoked, however, was very low
(on average <1 cigarette/day), moreover participants were asked to avoid supplements use
in the day before blood testing. Interestingly, a study [32] performed in post-menopausal
women showed that folate administration, in the form of 5-methyltetrahydrofolate (5-
MTHF), can reduce blood oxidative stress as assessed by FORT values reduction. Particular
effects of supplements and/or drugs will require specific further research [56].
Elevated BMI is known to increase systemic oxidative stress in the general popula-
tion [57], and in active adults [34]. Confirmatory with other studies, we found that BMI
was positively correlated to the FORT levels in non-OC-user women, but not in OC-users.
A similar finding was seen previously in female athletes [18]. Apparently, the strong OC
induction of oxidative stress cancelled benefits deriving from reduced BMI.
Results of our current study performed on the general female population concur with
a previous investigation evaluating oxidative stress in female athletes [18] founding that
42 OC-users had significantly higher hydroperoxides than 102 non-OC-users (OR = 42,
95%CI = 12–149, p < 0.001). However, that study did not measured hsCRP [18].
Consistently with the present study, a research conducted in 40–48 years old Belgian
women found a significant increase of lipid peroxides in 209 OC-users compared to 119 non-
users of contraception [23]. Additionally, a study comparing 32 OC-users with 30 non-
OC-users found increased lipid peroxides (+176%, p < 0.001) and oxidized LDLs (+45%,
p < 0.002) in the former group of women [21].
Interesting studies [22,33], investigating the time-course of hydroperoxide elevation
in women users of a low estrogen dose pill containing drospirenone, demonstrated that
oxidative stress increased significantly after only one week of OC use, remained constantly
elevated during OC use, and returned to basal levels within one week of OC discontinua-
tion, thus suggesting a causative role of OC use in increasing oxidative stress [33].
Mechanisms leading to elevation of hydroperoxides by OC are still not definitively
characterized [33], however, some evidence point to oxidative hepatotoxicity of OC [12].
P450 cytochromes (CYPs) catabolizing exogenous hormones can cause increased ROS
production [58] and, in turn, hyper-production of free radicals could provoke depletion of
antioxidant defenses such as depletion of reduced glutathione [33,35]. However, the role of
estrogens and progestogens in OC induced oxidative stress is still debated [21,33,59]. An
in vitro study showed that beta-estradiol treatment of cells was cytotoxic through oxidative
stress inducing a significant increase in lipid peroxidation [60].
By recent evidence tissue redox status is adequately reflected by redox blood biomark-
ers [61], thus, the increased oxidative stress measured in blood associated to OC use likely
parallels increased free radicals also in several body organs [62].
4.2. C-Reactive Protein
In the present study, OC-use significantly increased all risky levels of hsCRP, while
provoking a loss of the protective levels below 0.5 mg/L. Specifically, OC-users were more
likely to have hsCRP levels ≥ 2 mg/L (crude OR = 6.64, adjusted OR = 11.1) and ≥3 mg/L
(crude OR = 6.71, adjusted OR = 8.05) than non-OC-users, two cutoff values associated with
CVD risk. These results are consistent with previous Italian studies performed in 77 third
generation pill OC-users (OR = 4.04; 95% CI 1.99–8.18, p < 0.001 for hsCRP ≥ 3 mg/L) [24]
and 53 OC-users athletes (OR = 13.3, 95% CI 4.14–42.6, p < 0.001 for hsCRP ≥ 3 mg/L) [25]
and with a large Danish study finding low-grade inflammation (hsCRP 3–10 mg/L) in
29.9% of OC-users compared to 7.9% in non-OC users [27].
The role of hsCRP attesting low-grade inflammation in women was highlighted
by large studies (41, 58). An American study demonstrated that women who developed
cardiovascular events had higher baseline hsCRP levels than control subjects, so that hsCRP
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was a strong independent risk factor for any vascular event (RR = 4.8; 95%CI = 2.3–10.1)
and for myocardial infarction or stroke (RR = 7.3; 95%CI = 2.7–19.9) [63]. Further studies
confirmed the key role of chronic low-grade hsCRP for risk of future CVDs in women [41].
Recent evidence supports a role of chronic inflammation for female cancers [14,64,65].
Notably, combined estrogen plus progestogen contraceptives are considered human car-
cinogens and classified in Group 1 by the International Agency for Research on Cancer [14]
for the liver and bile duct, breast and uterine cervix cancer.
Moreover, combined oral contraceptives may affect the mediators of low-grade chronic
inflammation with potential additive risk in women with polycystic ovary syndrome
(PCOS); however clinical implications of OC use by PCOS patients need further studies [30].
New evidence suggests that inflammation [16] and oxidative stress [36] are impli-
cated in the aetiology of depression and disturbed sleep [66]; in turn, OC use has been
associated with depression [17]. More longitudinal research is needed to improve the
understanding of mechanisms induced by inflammation in OC-users possibly affecting the
psyconeurological pathways [67].
4.3. Correlation between Oxidative Stress and hsCRP
Overall, our data highlighted a strong positive correlation of oxidative stress with
hsCRP (p < 0.001) in healthy young women; women with oxidative stress over 400 FORT
Units were about eight time as likely to have hsCRP ≥ 2.0 mg/L. So far, there has been a
limited focus on this relationship specifically in women without pathologies.
There is scientific evidence demonstrating elevation of oxidative stress and inflam-
mation in several pathological conditions, particularly of vascular nature [68]. Correlation
between hsCRP and blood markers of oxidative stress was observed for instance in acute
myocardial infarction [69] and in patients with high risk of CVD [70]. The novelty of our
study is finding such a correlation in healthy subjects, suggesting that some general physi-
ological mechanism links oxidative stress and low-grade inflammation even in the absence
of evident pathologies. Such effects are likely mediated by factors like nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) and nuclear erytroid 2 like factor-2 (Nrf2),
two main transcription factors modulating several genes implicated both in oxidative stress
and inflammation, through a complex balance among a variety of factors [71].
In our study causality cannot be inferred, because the design of the study does
not allow to determine whether oxidative stress induces inflammation and/or whether
the increase of hsCRP provokes hydroperoxidation. It is to mention, however, that the
nuclear factors NF-kB and Nrf2 are key molecular switches both in oxidative stress and
inflammation pathways [38,71], thus, molecular mechanisms could activate at the same
time oxidative stress and inflammation.
In OC-users we found a higher frequency of elevated oxidative stress and inflamma-
tion compared to non-OC-users. dos Santos and colleagues [31] hypothesized that several
mechanisms, including oxidative stress, elevate inflammation in hormonal contraception
users, suggesting a causative role of oxidative stress in blood hsCRP increase. The biochem-
ical pathways linking oxidative stress and inflammation elevation have, however, to be still
completely elucidated, in particular in view of their potential adverse effects, including for
example thromboembolic events, endothelial damage, CVDs, and cancer [50,72].
4.4. Impact of the Composition of the Contraceptive Pill
Accumulating evidence suggests that the progestin component of combined contracep-
tive pills may be important in determining the side effects of OC use [2,5,20]. Specifically,
recent studies demonstrated that hormonal contraception can modify the redox status in
the vasculature of women using combined contraceptive pills containing low doses of
ethinyl-estradiol and progestin agents such as drospirenone [21,73] or norethisterone [19].
New generations of OC pills are characterized by lower estrogen content and by
newer progestins, like desogestrel, gestodene, cyproterone, and drospirenone with lower
androgenicity than past generation pills [59]. They have been introduced to reduce se-
Molecules 2021, 26, 1070 11 of 16
vere adverse effects of OC use, especially thromboembolism, and other cardiovascular
diseases [11]. However, these new OC preparations are still associated with the risk of
pulmonary embolism, myocardial infarction, thrombotic stroke and VTE [2,59]. A meta-
analysis of observational studies [6] found that all four generations of progestin were
associated with an elevated risk of ischemic stroke, and with a higher first-ever ischemic
stroke risk associated with current OC use compared with non-current OC use (overall sum-
mary OR = 2.47, 95%CI = 2.04–2.99). The risk of ischemic stroke among current OC-users
decreased significantly with decreasing estrogen dose: OCs of ≥50 µg ethinyl-estradiol (EE)
had OR = 3.28 (95%CI = 2.49–4.32), 30–40 µg EE OR = 1.75 (95%CI = 1.61–1.89), 20 µg EE
OR = 1.56 (95%CI = 1.36–1.79), whereas progestin only pills had not significant OR = 0.99
(95%CI = 0.71–1.37) [6].
A Danish study [2] examined 1,626,158 nonpregnant women, 15–49 years-old, with no
history of CVD or cancer. As compared with non-users, current use of OCs was associated
with an absolute increased risk of thrombotic stroke and myocardial infarction, ranging
from 0.9 to 1.7 for OC containing 20 µg EE, and ranging from 1.3 to 2.3 for preparations
with 30 to 40 µg EE, with relatively small differences in risk according to progestin type [2].
The risk of VTE associated to OC use is of particular concern and has been recently
investigated in a total of 10,562 cases of thromboembolism [5]. In respect to no exposure
to OCs in the previous year, exposure to OC containing desogestrel had increased risk
with OR of 4.28, cyproterone 4.27, drospirenone 4.12, gestodene 3.64, norethisterone 2.56,
norgestimate 2.53, and levonorgestrel 2.38 [5]. Similarly, another study [74] found that
the relative risk of VTE for combined oral contraceptives with 30–35 µg ethinyl-estradiol
and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about
50%–80% higher than for combined oral contraceptives with levonorgestrel.
In our study we did not find statically significant differences in hsCRP values be-
tween users of second, third and fourth generation pills. However, second generation
pill containing levonorgestrel had lower FORT values than third and fourth generation
pills. Notably the group of OC containing desogestrel, cyproterone, and drospirenone
had higher hydroperoxides values compared to all other progestins. A relevant issue for
future investigations is to assess whether increased risk of thromboembolism in OC-users
is mediated by the increased oxidative stress and/or chronic low-grade inflammation.
4.5. Strengths and Limitations
Limitations of our study include the recruitment of young adult Caucasian females,
and thus, results cannot be generalized to older women and/or to women with different
ethnic backgrounds; only women taking monophasic combined contraceptive pills were
included in the study, excluding other types of contraceptive drugs; OCs were heteroge-
neous in type and amount of hormonal components although the majorities were OCs of
third generation; detailed data about composition and dosing of potentially antioxidant
supplements like vitamin E, C, and β-carotene were not registered [33,35].
Strengths of the present study include assessment of oxidative stress and hsCRP and
several lifestyles and alimentary habits, the homogeneous ethnic group, the rather narrow
age range of women, and strictly healthy subject inclusion. Of note, all study women were
recruited before September 2019, thus avoiding any possible confounding by unrecognized
SARS-Cov2 infection, although in our opinion it will be interesting in the future to explore
the role of hormonal contraception in SARS-Cov2 infection.
5. Conclusions
This study adds to the existing evidence that OC use alters the oxidative homeostasis
and modifies low-grade inflammatory status of young women. We found very high oxida-
tive stress in the vast majority of OC-users (77% of them had FORT ≥ 400 Units). The strong
positive relationship, that we observed in healthy women, between oxidative stress and
basal chronic inflammation has several potential implications. Elevation of both parameters
can potentially concur in OC side effects like the increased risk of CVDs, cancer and other
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diseases, posing the question of medical eligibility criteria for contraceptive use [75,76], in
particular for women affected by major diseases like high risk of CVDs, having had cancer
or with major immune/inflammatory diseases like multiple sclerosis [77], diabetes [45,78]
or HIV infection [79,80]. It remains to be determined whether oxidative stress or hsCRP
elevation is the main driver of CVD risk and whether these two conditions are synergistic.
We also investigated lifestyle and alimentary habits of study women. OC-users
appear resilient to antioxidant food and low BMI protective effects. However, in our
opinion, future studies on food supplements having antioxidant and anti-inflammatory
roles [54,56,81,82] could be designed and especially targeted for OC-user women. Based
on our data, concurrent use of pro-oxidant [82] and/or proinflammatory [83] drugs in
addition to OC use should also be carefully taken into account, and will require future
investigations. We think advisable that, at least in women with pathologic conditions
and/or at high risk of developing a pathology, oxidative stress and hsCRP should be
monitored over OC time use.
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BMI Body mass index
CI Confidence interval
CVD Cardiovascular disease
FORT Free oxygen radical test
hsCRP High-sensitivity C-reactive protein
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NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells
Nrf2 Nuclear erytroid 2-like factor-2
OC Oral combined contraceptive
OR Odds ratio
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ROS Reactive oxygen species
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markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy. Mediators Inflamm.
2014, 2014, 147040. [CrossRef] [PubMed]
45. Francescato, M.P.; Stel, G.; Geat, M.; Cauci, S. Oxidative stress in patients with type 1 diabetes mellitus: Is it affected by a single
bout of prolonged exercise? PLoS ONE 2014, 9, e99062. [CrossRef]
46. Di Santolo, M.; Stel, G.; Banfi, G.; Gonano, F.; Cauci, S. Anemia and iron status in young fertile non-professional female athletes.
Eur. J. Appl. Physiol. 2008, 102, 703–709. [CrossRef] [PubMed]
47. Di Santolo, M.; Banfi, G.; Stel, G.; Cauci, S. Association of recreational physical activity with homocysteine, folate and lipid
markers in young women. Eur. J. Appl. Physiol. 2009, 105, 111–118. [CrossRef]
48. Casabellata, G.; Di Santolo, M.; Banfi, G.; Stel, G.; Gonano, F.; Cauci, S. Evaluation of iron deficiency in young women in relation
to oral contraceptive use. Contraception 2007, 76, 200–207. [CrossRef]
49. Kamhieh-Milz, J.; Salama, A. Oxidative stress is predominant in female but not in male patients with autoimmune thrombocy-
topenia. Oxid. Med. Cell. Longev. 2014, 2014, 720347. [CrossRef]
50. Halliwell, B. Free radicals and antioxidants: Updating a personal view. Nutr. Rev. 2012, 70, 257–265. [CrossRef] [PubMed]
51. Finkler, M.; Lichtenberg, D.; Pinchuk, I. The relationship between oxidative stress and exercise. J. Basic. Clin. Physiol Pharmacol
2014, 25, 1–11. [CrossRef] [PubMed]
Molecules 2021, 26, 1070 15 of 16
52. Lewis, N.A.; Newell, J.; Burden, R.; Howatson, G.; Pedlar, C.R. Critical Difference and Biological Variation in Biomarkers of
Oxidative Stress and Nutritional Status in Athletes. PLoS ONE 2016, 11, e0149927. [CrossRef] [PubMed]
53. Latif, R. Health benefits of cocoa. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16, 669–674. [CrossRef]
54. Serafini, M.; Peluso, I. Functional Foods for Health: The Interrelated Antioxidant and Anti-Inflammatory Role of Fruits, Vegetables,
Herbs, Spices and Cocoa in Humans. Curr. Pharm. Des. 2016, 22, 6701–6715. [CrossRef] [PubMed]
55. Saita, E.; Kondo, K.; Momiyama, Y. Anti-Inflammatory Diet for Atherosclerosis and Coronary Artery Disease: Antioxidant Foods.
Clin. Med. Insights Cardiol. 2015, 8, 61–65. [CrossRef]
56. Ricelli, A.; Gionfra, F.; Percario, Z.; De Angelis, M.; Primitivo, L.; Bonfantini, V.; Antonioletti, R.; Bullitta, S.M.; Saso, L.; Incerpi, S.;
et al. Antioxidant and Biological Activities of Hydroxytyrosol and Homovanillic Alcohol Obtained from Olive Mill Wastewaters
of Extra-Virgin Olive Oil Production. J. Agric. Food Chem. 2020, 68, 15428–15439. [CrossRef] [PubMed]
57. Keaney, J.F., Jr.; Larson, M.G.; Vasan, R.S.; Wilson, P.W.; Lipinska, I.; Corey, D.; Massaro, J.M.; Sutherland, P.; Vita, J.A.; Benjamin,
E.J.; et al. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study. Arter. Thromb.
Vasc. Biol. 2003, 23, 434–439. [CrossRef] [PubMed]
58. Modugno, F.; Knoll, C.; Kanbour-Shakir, A.; Romkes, M. A potential role for the estrogen-metabolizing cytochrome P450 enzymes
in human breast carcinogenesis. Breast Cancer Res. Treat. 2003, 82, 191–197. [CrossRef]
59. Sitruk-Ware, R.; Nath, A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills.
Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27, 13–24. [CrossRef]
60. Yedjou, C.; Cameron, J.; Mbemi, A.T.; Tchounwou, P. b-estradiol induces cytotoxic effects to human T-lymphoma (Jurkat) cells
through oxidative stress. J. Miss Acad. Sci. 2015, 60, 279–283.
61. Margaritelis, N.V.; Veskoukis, A.S.; Paschalis, V.; Vrabas, I.S.; Dipla, K.; Zafeiridis, A.; Kyparos, A.; Nikolaidis, M.G. Blood reflects
tissue oxidative stress: A systematic review. Biomarkers 2015, 20, 97–108. [CrossRef] [PubMed]
62. Savage, K.J.; Clarkson, P.M. Oral contraceptive use and exercise-induced muscle damage and recovery. Contraception 2002,
66, 67–71. [CrossRef]
63. Ridker, P.M.; Buring, J.E.; Shih, J.; Matias, M.; Hennekens, C.H. Prospective study of C-reactive protein and the risk of future
cardiovascular events among apparently healthy women. Circulation 1998, 98, 731–733. [CrossRef]
64. Tang, R.; Ye, X.; Chen, S.; Ding, X.; Lin, Z.; Zhu, J. Pregravid Oral Contraceptive Use and the Risk of Preterm Birth, Low Birth
Weight, and Spontaneous Abortion: A Systematic Review and Meta-Analysis. J. Womens Health (Larchmt.) 2019. [CrossRef]
[PubMed]
65. Peres, L.C.; Mallen, A.R.; Townsend, M.K.; Poole, E.M.; Trabert, B.; Allen, N.E.; Arslan, A.A.; Dossus, L.; Fortner, R.T.; Gram, I.T.;
et al. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian
Cancer Cohort Consortium. Cancer Res. 2019, 79, 5442–5451. [CrossRef]
66. Okun, M.L.; Coussons-Read, M.; Hall, M. Disturbed sleep is associated with increased C-reactive protein in young women. Brain
Behav. Immun. 2009, 23, 351–354. [CrossRef] [PubMed]
67. Lewis, C.A.; Kimmig, A.S.; Zsido, R.G.; Jank, A.; Derntl, B.; Sacher, J. Effects of Hormonal Contraceptives on Mood: A Focus on
Emotion Recognition and Reactivity, Reward Processing, and Stress Response. Curr. Psychiatry Rep. 2019, 21, 115. [CrossRef]
68. Steven, S.; Frenis, K.; Oelze, M.; Kalinovic, S.; Kuntic, M.; Bayo Jimenez, M.T.; Vujacic-Mirski, K.; Helmstädter, J.; Kröller-Schön,
S.; Münzel, T.; et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxidative Med. Cell.
Longev. 2019, 2019, 7092151. [CrossRef]
69. Baruah, M. C-Reactive Protein (CRP) and Markers of Oxidative Stress in Acute Myocardial Infaction. In Clinical Significance of
C-Reactive Protein; Springer: Singapore, 2020; pp. 95–115.
70. Il’yasova, D.; Ivanova, A.; Morrow, J.D.; Cesari, M.; Pahor, M. Correlation between two markers of inflammation, serum C-reactive
protein and interleukin 6, and indices of oxidative stress in patients with high risk of cardiovascular disease. Biomarkers 2008,
13, 41–51. [CrossRef]
71. Saha, S.; Buttari, B.; Panieri, E.; Profumo, E.; Saso, L. An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation.
Molecules 2020, 25, 5474. [CrossRef] [PubMed]
72. Saghazadeh, A.; Hafizi, S.; Rezaei, N. Inflammation in venous thromboembolism: Cause or consequence? Int. Immunopharmacol.
2015, 28, 655–665. [CrossRef] [PubMed]
73. Massart, A.; Portier, H.; Rosado, F.; Toumi, H.; Filaire, E. Lipid Peroxidation in Judoists Using Oral Contraceptives. Int. J. Sports
Med. 2012, 33, 781–788. [CrossRef] [PubMed]
74. de Bastos, M.; Stegeman, B.H.; Rosendaal, F.R.; Van Hylckama Vlieg, A.; Helmerhorst, F.M.; Stijnen, T.; Dekkers, O.M. Combined
oral contraceptives: Venous thrombosis. Cochrane Database Syst. Rev. 2014, 3. [CrossRef] [PubMed]
75. Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use, (US MEC).
2016. Available online: https://www.cdc.gov/reproductivehealth/contraception/contraception_guidance.htm (accessed on
15 January 2021).
76. World Health Organization (WHO). Medical Eligibility for Contraceptive Use. Fifth Edition. Executive Summary. 2015. Avail-
able online: https://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/ (accessed on 15 January 2021).
77. Houtchens, M.K.; Zapata, L.B.; Curtis, K.M.; Whiteman, M.K. Contraception for women with multiple sclerosis: Guidance for
healthcare providers. Mult. Scler. 2017, 23, 757–764. [CrossRef]
Molecules 2021, 26, 1070 16 of 16
78. O’Brien, S.H.; Koch, T.; Vesely, S.K.; Schwarz, E.B. Hormonal Contraception and Risk of Thromboembolism in Women with
Diabetes. Diabetes Care 2017, 40, 233–238. [CrossRef] [PubMed]
79. Centers for Disease Control and Prevention (CDC). Morbidity and Mortality Weekly Report (MMWR). 2017. Available on-
line: https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixc_tableC1.html#mec_hiv (accessed on
15 January 2021).
80. World Health Organization (WHO). Contraceptive Eligibility for Women at High Risk of HIV. Guidance Statement-
Recommendations on Contraceptive Methods Used by Women at High Risk of HIV. 2019. Available online: https:
//www.who.int/reproductivehealth/publications/contraceptive-eligibility-women-at-high-risk-of-HIV/en/ (accessed on
15 January 2021).
81. Franco, R.; Martinez-Pinilla, E. Chemical rules on the assessment of antioxidant potential in food and food additives aimed at
reducing oxidative stress and neurodegeneration. Food Chem. 2017, 235, 318–323. [CrossRef]
82. Salimi, A.; Neshat, M.R.; Naserzadeh, P.; Pourahmad, J. Mitochondrial Permeability Transition Pore Sealing Agents and
Antioxidants Protect Oxidative Stress and Mitochondrial Dysfunction Induced by Naproxen, Diclofenac and Celecoxib. Drug Res.
(Stuttg.) 2019, 69, 598–605. [CrossRef] [PubMed]
83. McComsey, G.A.; Kitch, D.; Daar, E.S.; Tierney, C.; Jahed, N.C.; Melbourne, K.; Ha, B.; Brown, T.T.; Bloom, A.; Fedarko,
N.; et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or
atazanavir/ritonavir. AIDS 2012, 26, 1371–1385. [CrossRef]
